Michael W. Kattan, Ph.D.
Quantitative Health Sciences /JJN3
Telephone: (216)444-0584
Fax: (216)445-2781
kattanm@ccf.org

Positions:
Chair, Quantitative Health Sciences,
Cleveland Clinic, 2004-present

Professor of Medicine, Epidemiology and Biostatistics, Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University, 2006-present

Education:
PhD, Management Information Systems, University of Houston, 1993
Postdoc, Medical Informatics, Baylor College of Medicine, 1994

Honors/Service:
Associate Editor, Urologic Oncology, 1999-2002
Associate Editor, Urologic Oncology: Seminars and Original Investigations, 2003-Present
Board of Consultants, Journal of Urology, 1996 - 2007
Editorial Board, Medical Decision Making, 1997-2000, 2005-2008
Section Editor, Clinical Prostate Cancer, 2002-Present
Advisory Board, Nature Clinical Practice Urology, 2005-Present

Key Interests:
Dr. Kattan is interested in the development, validation, and use of prediction models.  He has developed several such models in cancer and released them as freely available software, from http://www.nomograms.org.   Dr. Kattan is also interested in quality of life assessment to support medical decision making, such as utility assessment.  He is also interested in decision analysis and cost-effectiveness analysis.

Selected Publications: (Click here for complete PubMed listing)
Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst. 2003;95:634-635.

Kattan MW, Heller G, Brennan MF. A competing-risks nomogram for sarcoma-specific death following local recurrence. Stat Med 2003; 22: 3515-3525.

Kattan MW. Comparison of Cox regression with other methods for determining prediction models and nomograms. J Urol 2003; 170: S6-S10.

Littenberg B, Partilo S, Licata A, Kattan MW. Paper Standard Gamble: The reliability of a paper questionnaire to assess utility. Medical Decision Making 2003; 23(6): 480-488.

Kattan MW. Comparing treatment outcomes using utility assessment for health-related quality of life. Oncology 2003; 17(12): 1687-1693.

Kattan MW. Evaluating a new marker’s predictive contribution. Clin Can Res 2004; 10: 882-824.

Kattan MW, Vickers AJ. Incorporating predictions of individual patient risk in clinical trials. Urol Oncol. 2004 Jul-Aug;22(4):348-52.

Vickers AJ, Kattan MW, Sargent D. Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials. 2007 June 5;8(1):14.

Nam RK, Toi, A, Klotz LK, Trachtenberg J, Jewett MAS, Appu S, Loblaw DA, Sugar L, Narod SA, Kattan MW. Assessing individual risk for prostate cancer. J Clin Oncol. 2007 Aug 20;25(24):3582-3588.

Heller G, Kattan MW, Scher HI. Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data. Med Decis Making. 2007, Jul-Aug;27(4):380-386.

Patents:

My CV
Biographical Sketch